GvHD Pipeline 2026: Cell-Based, Microbiome and Targeted Therapies Reshape Treatment Landscape
核心洞察
The global GvHD pipeline now spans 45+ companies developing 50+ therapies, including microbiome-based, cellular, monoclonal antibody and small-molecule candidates targeting acute, chronic and prophylactic settings.
Orca Bio (搜索)'s Tregzi (搜索) (Orca-T) received FDA approval in June 2026, with Phase III data showing 78% of patients GvHD-free at one year versus 38% for standard transplants.
MaaT Pharma (搜索)'s MaaT013 achieved a 62% 28-day gastrointestinal overall response rate in third-line GI-aGvHD, surpassing the 38% expected threshold in the Phase 3 ARES trial.
The graft-versus-host disease (搜索) (GvHD) therapeutic landscape is entering a period of substantial clinical and commercial change, driven by an expanding pipeline of cell-based immunomodulators, microbiome-restorative therapies, targeted biologics and small molecules. According to DelveInsight's "Graft vs Host Disease Pipeline Insight, 2026" report, more than 45 companies are advancing over 50 treatment candidates globally, spanning acute GvHD, chronic GvHD and prophylaxis.
The shift toward more precise disease control, prevention, immune tolerance and tissue repair is expected to create meaningful opportunities for both established market leaders and emerging GvHD companies through 2036, according to a separate market and epidemiology forecast covering the seven major markets (7MM).
Cell-Based Therapies Advance Toward Approval
A defining development in the field came in June 2026, when the U.S. FDA approved Tregzi (搜索) (Orca-T), an allogeneic regulatory T-cell therapy developed by Orca Bio (搜索), for use in adults with hematologic malignancies undergoing allogeneic stem cell transplantation. Clinical trial results showed a marked improvement in one-year survival without moderate-to-severe chronic GvHD compared with conventional transplant approaches.
The therapy's efficacy was underscored by results from the Phase III Precision-T trial (NCT05316701), presented in March 2025, which showed that 78% of patients treated with Orca-T (TRGFT-201) were GvHD-free after one year, compared with only 38% in the group receiving standard allogeneic stem cell transplants — more than doubling the rate of patients remaining free from moderate-to-severe chronic GvHD. Orca-T is designed to minimize transplant-related complications while promoting immune system recovery.
In April 2025, the California Institute for Regenerative Medicine (CIRM) granted $8 million to biotech firm Tr1X (搜索) to advance its Phase I/IIa clinical trial of TRX103, an allogeneic, engineered type 1 regulatory (Tr1) Treg cell therapy intended to prevent GvHD in blood cancer patients receiving mismatched stem cell transplants.
Microbiome Therapies Show Promise in Refractory Disease
Microbiome-based approaches are emerging as a notable frontier, particularly for difficult-to-treat gastrointestinal acute GvHD. MaaT Pharma (搜索)'s MaaT013, a pooled-donor microbiome ecosystem therapy, is being evaluated for gastrointestinal-predominant, steroid-refractory acute GvHD, with a pivotal Phase III program ongoing and a European marketing authorization application submitted in June 2025. The candidate has also received orphan drug designation from the U.S. FDA and the European Medicines Agency.
In January 2025, MaaT Pharma (搜索) announced positive topline results from its pivotal Phase 3 ARES trial, a single-arm, open-label, multicenter study conducted across Europe. The study assessed MaaT013 in patients with acute GvHD involving the gastrointestinal tract (GI-aGvHD) who were in third-line treatment — resistant to steroids and either refractory or intolerant to ruxolitinib. The trial achieved its primary endpoint with a 28-day gastrointestinal overall response rate (GI-ORR) of 62%, significantly surpassing the expected rate of 38%, as evaluated by an Independent Review Committee.
Targeted Small Molecules and Biologics
The marketed and late-stage landscape continues to diversify across mechanisms of action. Ruxolitinib remains a leading revenue-generating GvHD therapy, supported by approvals for steroid-refractory acute and chronic GvHD in major markets. Ibrutinib is established in chronic GvHD after prior systemic treatment, while belumosudil provides selective ROCK2 (搜索) inhibition for previously treated chronic GvHD. Axatilimab-csfr expands the treatment landscape through CSF-1R (搜索) inhibition, targeting monocyte- and macrophage-associated inflammation and fibrosis.
In January 2026, REZUROCK (belumosudil) received a positive re-examination opinion from the European Medicines Agency (EMA), recommending conditional marketing authorization for the treatment of chronic GvHD following the resolution of earlier concerns related to its marketing application.
Prominent investigational candidates in the pipeline include MaaT013 (XERVYTEG), RGI-2001, CYP-001, ivarmacitinib, siplizumab and itolizumab. RGI-2001 is in development for acute GvHD prophylaxis and has generated positive Phase IIb findings supporting plans for further late-stage evaluation. CYP-001 has been studied in combination with corticosteroids for high-risk acute GvHD under a cleared U.S. FDA investigational new drug application. Selected pipeline therapies are anticipated to reach the U.S. market before 2028, subject to successful clinical and regulatory outcomes.
Prophylaxis and Unmet Needs
In June 2025, results from the Phase 3 BM12 CAST trial (ACTRN12618000505202), presented at the 2025 European Hematology Association Congress, showed that cyclophosphamide combined with cyclosporin, a calcineurin inhibitor, significantly improved GvHD-free relapse-free survival compared to standard prophylaxis in patients with aggressive blood cancers undergoing stem cell transplants from matched related donors with either reduced-intensity or myeloablative conditioning.
Despite recent progress, significant unmet needs remain. Existing prophylactic approaches may provide suboptimal protection in high-risk transplant settings and can be associated with cumulative toxicity. Priorities identified across the market include earlier diagnosis, improved risk stratification, optimized combination regimens, durable immune tolerance, enhanced understanding of chronic GvHD pathophysiology, and safer treatments for refractory disease.
Key companies active in the GvHD market include AbbVie, Johnson & Johnson, Sanofi, Incyte, Syndax Pharmaceuticals, Novartis, Neovii, Mundipharma, Shionogi, JCR Pharmaceuticals, Bristol Myers Squibb, MaaT Pharma (搜索), REGiMMUNE, and other biotechnology and pharmaceutical developers.